← Back to Search

Other

Molecular Tumor Board (MTB)-recommended matched therapy for Pancreatic Cancer (PROTECT-PANC Trial)

Q: Are there any ongoing efforts to enroll participants for this clinical trial at the moment?

<p>According to the information provided on clinicaltrials.gov, this particular study is no longer actively seeking participants. Its initial posting date was March 1st, 2024, and it was last updated on January 18th, 2024. However, there are currently a total of 1670 other ongoing studies that are actively recruiting patients at this time.</p>

N/A

Recruiting

Led By Razelle Kurzrock, MD

Research Sponsored by Medical College of Wisconsin

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Laboratory values: Absolute neutrophil count (ANC) ≥ 1.0 × 109/L, Platelet count ≥ 75,000/mm^3 (125 × 109/L), Hemoglobin (Hgb) ≥ 8 g/dL, aspartate aminotransferase (AST) serum glutamic-oxaloacetic transaminase (SGOT), alanine transaminase (ALT) serum glutamate-pyruvate transaminase (SGPT) ≤ 5 × upper limit of normal range (ULN), Eastern Cooperative Oncology Group (ECOG) Performance Status < 3

Pathologically confirmed pancreatic cancer (excluding neuroendocrine histology)

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 12 months

Awards & highlights

PROTECT-PANC Trial Summary

This trial is a study that aims to test the effectiveness and safety of personalized treatments for patients with pancreatic cancer who are at a high risk of the cancer coming back after surgery.

Who is the study for?

This trial is for individuals who have had surgery for pancreatic cancer and are at high risk of the cancer coming back. Specific details about who can join or reasons why someone might not be eligible to participate are not provided.Check my eligibility

What is being tested?

The study is looking into how safe and effective personalized treatments are for patients with pancreatic cancer that's likely to return after surgery. It involves giving therapies that match each patient's unique molecular profile.See study design

What are the potential side effects?

Details on side effects are not specified, but typically, individualized cancer therapies may include risks such as allergic reactions, fatigue, nausea, and other drug-specific side effects.

PROTECT-PANC Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My cancer is a type of pancreatic cancer, not related to neuroendocrine cells.

Select...

I am 18 years old or older.

Select...

I can swallow and keep down pills.

Select...

I haven't taken any cancer drugs for at least 3 weeks or 5 half-lives of the drug, whichever is shorter.

Select...

I have agreed to follow the treatment plan recommended by the Molecular Tumor Board.

PROTECT-PANC Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ six months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~six months

This trial's timeline: 3 weeks for screening, Varies for treatment, and six months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Adverse Events

Disease-free Survival

PROTECT-PANC Trial Design

1Treatment groups

Experimental Treatment

Group I: Molecular Tumor Board (MTB)-recommended matched therapyExperimental Treatment1 Intervention

The MTB, a multidisciplinary group composed of medical oncologists (including those with expertise in precision oncology), surgical oncologists, and a pathologist, convenes periodically to discuss and recommend an individualized treatment plan that targets specific molecular alterations (e.g., genomic mutations) found in the patient's cancer while considering patient clinical and laboratory factors.

0 / 6Eligibility criteria met

Find a Location

Who is running the clinical trial?

Medical College of WisconsinLead Sponsor

610 Previous Clinical Trials

1,162,673 Total Patients Enrolled

Razelle Kurzrock, MDPrincipal InvestigatorMedical College of Wisconsin

9 Previous Clinical Trials

110,650 Total Patients Enrolled

Mandana Kamgar, MD, MPHPrincipal InvestigatorMedical College of Wisconsin

2 Previous Clinical Trials

64 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any ongoing efforts to enroll participants for this clinical trial at the moment?

"According to the information provided on clinicaltrials.gov, this particular study is no longer actively seeking participants. Its initial posting date was March 1st, 2024, and it was last updated on January 18th, 2024. However, there are currently a total of 1670 other ongoing studies that are actively recruiting patients at this time."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Molecular Profile-related Individualized Targeted Therapy in Resected Pancreatic Cancer With High-Risk of Cancer Recurrence

Mandana Kamgar, MD 2024. "Molecular Profile-related Individualized Targeted Therapy in Resected Pancreatic Cancer With High-Risk of Cancer Recurrence". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06228599.

All > Chicago > Milwaukee